BioSpace News Archive

Aspen Medical Products, the industry leader in spine solutions for pain and mobility management, has launched the VRTX System – the first fully integrated spinal support system on the market for post-operative and trauma care.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from the largest study to date on uncertain results from hereditary disease genetic testing.

Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country.

The Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the screening, diagnosis and treatment of patients living with pulmonary hypertension related to interstitial lung disease.

Fermata, an outpatient psychiatric center of excellence, today announced a new clinical trial to study the SAINT™ Neuromodulation System for treating major depressive disorder (MDD) as part of a larger multi-site trial to further develop a more rapid, personalized treatment option for treatment-resistant major depression.

EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy (CRT) in the United States have been published in The Journal of American College of Cardiology (JACC).

Valneva SE announces the submission of a marketing application with the European Medicines Agency for approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553.

Orthopaedic Solutions Management, a physician-led orthopedic focused management services organization, is proud to announce its expansion into two new Florida markets, Gainesville and Ocala.

ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, announces a peer-reviewed publication in Nature Communications, showcasing the potential of its proprietary dual adeno-associated virus (AAV) vector technology based on mRNA trans-splicing, REVeRT (REconstitution Via mRNA Trans-splicing).

Abbott (NYSE: ABT) today announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK) in people with chronic limb-threatening ischemia (CLTI).